PacBio and Intus Bio launch GutID, a groundbreaking gut health test utilizing advanced sequencing and AI for microbiome analysis.
Quiver AI Summary
PacBio and Intus Bio have launched GutID, the first commercial human gut health test that combines Intus Bio's Titan-1 platform with PacBio's HiFi sequencing technology. This innovative test offers the most detailed and accurate gut microbiome analysis available, providing strain-level insights that can aid in health management, particularly for conditions like cancer and chronic diseases. GutID allows users to collect samples at home, which are then analyzed at a lab, producing comprehensive reports that include a proprietary microbiome health score and personalized recommendations. Healthcare professionals recommend GutID for its ability to deliver reliable results and actionable insights, marking a significant advancement in microbiome research and its implications for human health. The test is now available for purchase at gutid.com.
Potential Positives
- PacBio and Intus Bio have launched GutID, the first commercial human gut health test, showcasing their collaboration and innovation in microbiome research.
- GutID utilizes PacBio's HiFi sequencing technology, known for its high accuracy, enhancing the reliability of gut microbiome testing.
- The test provides comprehensive, actionable insights into gut health, targeting conditions like IBS and IBD, which could increase demand and sales.
- GutID's launch positions PacBio at the forefront of a growing market focused on personalized health and microbiome technologies.
Potential Negatives
- The press release includes a caution about "forward-looking statements," indicating the company recognizes potential risks and challenges related to the commercialization of GutID, which could significantly impact future performance.
- Despite the optimistic tone, the statement acknowledges inherent risks in generating discoveries in the microbiome, suggesting uncertainties about the technology's overall effectiveness and reliability.
- The warning about third-party claims relating to intellectual property rights indicates potential legal vulnerabilities that could hinder product development or lead to financial implications for the company.
FAQ
What is GutID?
GutID is a commercial human gut health test that combines Intus Bio’s Titan-1 platform with PacBio’s HiFi sequencing technology.
How does GutID improve gut health testing?
GutID provides strain-level resolution and high accuracy, offering comprehensive insights into the microbiome that previous tests lacked.
Who can benefit from using GutID?
Individuals with conditions like IBS, IBD, and those interested in improving gut health and longevity can benefit from GutID.
How is the sample collected for GutID testing?
Users collect a sample easily from home and ship it to a state-of-the-art lab for analysis.
Where can I purchase GutID?
GutID is available for purchase at www.gutid.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PACB Insider Trading Activity
$PACB insiders have traded $PACB stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $PACB stock by insiders over the last 6 months:
- SUSAN G. KIM (See Remarks) sold 19,782 shares.
- CHRISTIAN O HENRY (See Remarks) sold 98,907 shares.
- JEFF EIDEL (See Remarks) sold 26,760 shares.
- OENE MARK VAN (See Remarks) sold 38,011 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PACB Hedge Fund Activity
We have seen 88 institutional investors add shares of $PACB stock to their portfolio, and 96 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 8,356,139 shares (-32.1%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 5,792,951 shares (+125.1%) to their portfolio in Q3 2024
- BANK OF NEW YORK MELLON CORP removed 4,362,004 shares (-43.9%) from their portfolio in Q3 2024
- EDMOND DE ROTHSCHILD HOLDING S.A. added 3,571,460 shares (+21.3%) to their portfolio in Q3 2024
- JACKSON SQUARE PARTNERS, LLC removed 2,587,327 shares (-29.1%) from their portfolio in Q3 2024
- D. E. SHAW & CO., INC. removed 1,645,499 shares (-100.0%) from their portfolio in Q3 2024
- VK SERVICES, LLC removed 1,316,391 shares (-50.0%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay and AI-powered analysis with PacBio’s renowned sequencing accuracy, GutID sets a new benchmark in gut microbiome testing, and is the only comprehensive and accurate gut microbiome test available today.
Offering the highest resolution analysis possible, GutID is a major breakthrough as it delivers robust and repeatable results, which can be used with confidence to help understand and manage the microbiome, a known critical driver of health outcomes including cancer.
“We are proud to partner with PacBio for their first human health-related commercial application,” said Paul Denslow, CEO of Intus Bio. “High accuracy, long-read sequencing is essential to Intus Bio’s ability to unlock the microbiome, making GutID not just a test, but a transformative tool for understanding and improving human health. It’s already having an incredible impact.”
Recommended by healthcare professionals, GutID provides previously unobtainable gut health information. The test lets the user easily collect and ship a sample from home to a state-of-the-art lab, where PacBio’s long-read sequencing and Intus Bio’s Titan-1 platform combine to power comprehensive, actionable reports.
Each report includes a detailed visualization of bacteria down to the strain level, showing the abundance of both commensals and pathogens. Users also receive a proprietary microbiome health score and personalized recommendations to optimize gut and overall wellness.
GutID is already transforming the lives of individuals with IBS, IBD, and those focused on longevity by offering insights which were previously unavailable.
“We are thrilled to see Intus Bio leveraging PacBio’s advanced sequencing solutions to uncover microbial communities far beyond traditional methods,” said David Miller, Vice President of Marketing at PacBio. GutID showcases the transformative power of our long-read sequencing platforms, opening new frontiers in healthcare by providing deeper insights into the human microbiome and improving human health.”
The microbiome - the vast collection of bacteria in every human - is well established as a critical driver of health outcomes. It has been associated with cancer, autoimmune, neurodegenerative, and other chronic diseases as well as behavioral disorders. A complete, accurate and detailed view of the bacterial microbiome is central to actionability, allowing interventions and lifestyle changes to be made and tracked with confidence.
Despite the microbiome’s well understood potential to impact healthcare, previous generations of microbiome tests have been low resolution, resulting in variable results and limited utility for improving and managing health. By combining Intus Bio’s strain-level microbiome platform and the power of PacBio’s sequencing technology, GutID offers both consumers and clinicians repeatable and robust results for actionable insights.
GutID is now available for purchase at
www.gutid.com
. For more information about the technology behind GutID and how it can support health and wellness, visit
www.intusbio.com
and
www.pacb.com
.
About PacBio:
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB
®
short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About Intus Bio
:
Intus Bio is transforming the role of the microbiome in healthcare through the development of cutting-edge technology to allow the complexity of the microbiome to be truly seen and understood for the first time. This approach is supporting next generation tests for patients and clinicians to improve health outcomes, and microbiome discoveries with the promise of a new class of tools for the detection, treatment, and prevention of chronic diseases. Powered by the proprietary Titan-1 platform, Intus Bio is making the microbiome as important to healthcare as it is to health.
Forward Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, coverage, advantages, and benefits or expected benefits of using, PacBio products or technologies, including the use of HiFi sequencing technology in connection with Intus Bio’s GutID; use of GutID to help understand and manage the microbiome and to open new frontiers in healthcare; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in commercializing a new product, the difficulty of generating discoveries in the microbiome; potential performance and quality issues; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
PacBio
For investors: Todd Friedman,
IR@pacificbiosciences.com
For media:
PR@pacificbiosciences.com
Intus Bio
For investors:
paul.denslow@intusbio.com
For media:
soo.kang@intusbio.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
